Business description
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs approximately 15,000 people, including around 2,400 scientists and technicians, at more than 45 facilities, and in fiscal year 2020 generated over $3 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey.
Management board & Supervisory board
| CEO |
| Alessandro Maselli |
| Management board |
| Matti Masanovich, Jonathan Arnold , Lorenzo Carletti, Steven Fasman, Joseph A. Ferraro, Karen Flynn, Aris Gennadios, Mike Grippo, Scott Gunther, Tom Hawkeswood, Ricky Hopson, Trish Hunt, Charles Lickfold, Karen Santiago, Ricardo Zayas, Lisa Evoli |
| Supervisory board |
| John Greisch, J. Martin Carroll, Madhavan Balachandran, Michael Barber, Rolf Classon, Rosemary Crane, Karen Flynn, Dr. Christa Kreuzburg, Gregory T. Lucier, Alessandro Maselli, Dr. Donald E. Morel, Jack Stahl, Frank A. D'Amelio, Michelle Ryan , Stephanie Okey |
Company data
| Name: |
Catalent Inc. |
| Address: |
14 Schoolhouse Road,Somerset, New Jersey 08873, USA |
| Phone: |
+1-732-537-6200 |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
https://www.catalent.com/ |
| Industry: |
Biotechnology |
| Sector: |
Biotechnology |
| Sub sector: |
Biotechnology |
| End of financial year: |
30/06 |
| Free Float: |
- |
| IPO date: |
31/07/2014 |
Investor relations
| Name: |
- |
| IR phone: |
+1-732-537-6325 |
| IR Fax: |
+1-732-537-5932 |
| IR e-mail: |
investors@catalent.com
|
